Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Curr Treat Options Oncol ; 22(1): 8, 2021 01 02.
Artigo em Inglês | MEDLINE | ID: mdl-33387071

RESUMO

OPINION STATEMENT: Despite extensive research that has identified new risk factors, genetic mutations, and therapeutic options, pancreatic ductal adenocarcinoma continues to be a leading cause of cancer related death. Patients with pancreatic cancer, along with their clinicians, must balance realistic hope alongside a life-threatening diagnosis. As the search for treatments to reduce the morbidity and mortality continues, symptom management and quality of life remain the focus of our efforts. In addition to side effects of cancer-directed therapy, patients are at risk for malnutrition, pain, and fatigue. These factors are often overlooked in practice, so a multidisciplinary team is critical in optimizing the care of patients.


Assuntos
Adenocarcinoma/terapia , Carcinoma Ductal Pancreático/terapia , Manejo da Dor , Dor/epidemiologia , Adenocarcinoma/complicações , Adenocarcinoma/epidemiologia , Adenocarcinoma/genética , Carcinoma Ductal Pancreático/complicações , Carcinoma Ductal Pancreático/epidemiologia , Carcinoma Ductal Pancreático/genética , Fadiga/complicações , Fadiga/epidemiologia , Fadiga/genética , Fadiga/terapia , Humanos , Mutação/genética , Dor/patologia , Cuidados Paliativos , Qualidade de Vida
2.
J Palliat Med ; 18(9): 786-9, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26107143

RESUMO

BACKGROUND: Continuous morphine infusions (CMIs) treat pain and dyspnea at the end of life (EOL). CMIs may be initiated at an empiric rate and/or are rapidly escalated without proper titration. OBJECTIVE: The study objective was to evaluate CMI patterns at the EOL. METHODS: This single-center, retrospective chart review evaluated adult patients who died while receiving CMI at EOL. Patient demographics and opioid dosing information were extracted from an electronic medical record. Twenty-four hour IV morphine equivalent was calculated prior to CMI initiation and at the time of death. RESULTS: Of the 190 patient charts, 63.2% (n=120) received no bolus doses prior to CMI initiation. Mean 24-hour IV morphine equivalent prior to CMI initiation was 49.3 mg (range: 0-1200 mg, SD 384.9) and at time of death was 267.1 mg (12.0-5193.2 mg, SD 442.2), representing an increase of +442%. Mean CMI starting rate was 3.3 mg/hour (0.4-30.0 mg/hour, SD 3.6) with titration at time of death to a mean of 7.7 mg/hour (0.4-70.0 mg/hour, SD 9.4), representing an increase of +130%. Mean number of CMI rate adjustments was 2.5 (0-5, SD 3.3); and number of bolus doses administered between titrations was 4.2 (0-27, SD 4.8). Mean time from CMI initiation to death was 15.5 hours (0.05-126.9 hours, SD 21.7). There was a negative association between rate of infusion increase per hour and total number of hours on CMI (r=-0.2, p=0.0062). CONCLUSIONS: Hospitalized patients at EOL had a much higher 24-hour IV morphine equivalents and CMI rates at time of death compared to CMI initiation. Variability was observed in the number of CMI rate adjustments and the number of bolus doses administered.


Assuntos
Analgésicos Opioides/administração & dosagem , Dispneia/tratamento farmacológico , Morfina/administração & dosagem , Manejo da Dor/métodos , Dor/tratamento farmacológico , Assistência Terminal , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Infusões Intravenosas , Pacientes Internados , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...